XBIT XBiotech Inc.

CIK 0001626878 10 ready 8-Ks latest December 9, 2025, 6:59 PM ET RSS · JSON

Activity: NORMAL 0 filings / 30d vs 0 baseline

Ready 8-Ks 10

Latest filing December 9, 2025, 6:59 PM ET

Top materiality 0.70

Event mix leadership ×4 · other ×3 · other_material ×1

Sentiment 2 pos · 0 neg · 8 neu

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for XBIT

Highest-materiality recent filing

XBiotech CEO John Simard retires; CSO Sushma Shivaswamy named interim CEO

December 9, 2025, 6:59 PM ET leadership materiality 0.70 neutral item 5.02

John Simard retired as CEO/President effective Dec 8, 2025; continues as Chairman.
Sushma Shivaswamy, 47, appointed interim CEO effective Dec 8, remains CSO.

Read filing →

December 9, 2025, 6:59 PM ET leadership materiality 0.70 neutral item 5.02

XBiotech CEO John Simard retires; CSO Sushma Shivaswamy named interim CEO

John Simard retired as CEO/President effective Dec 8, 2025; continues as Chairman.
October 15, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.02

XBiotech amends director bio: Rademaker is consultant to multiple PE firms

Clarifies Craig Rademaker is a consultant to several Canadian private equity firms, not a single firm.
October 3, 2025, 7:59 PM ET other materiality 0.60 neutral item 1.01 item 5.02 item 9.01

XBiotech enters new employment agreement with CEO John Simard; $1.25M salary, $4.53M bonus baseline

Base salary unchanged at $1.25M; annual bonus baseline set at $4.53M for 2025, both inflation-adjusted annually.
September 2, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

XBiotech Inc. Announces Results of Annual Meeting of Stockholders

Elected five directors: John Simard (12.37M for), Thomas Kündig (12.70M), Craig Rademaker (12.50M), Tevi D. Troy (12.30M), David Soffer (12.30M).
June 24, 2025, 7:59 PM ET leadership materiality 0.55 neutral item 5.02

XBiotech appoints Dr. Thomas Kündig and Craig Rademaker to Board of Directors

Dr. Thomas Kündig, Director of Dermatology at University Hospital Zurich, appointed to Board and Compensation Committee effective June 24, 2025.
April 7, 2025, 7:59 PM ET regulatory materiality 0.30 neutral item 3.01

Director W. Thorpe McKenzie retires; XBiotech to maintain one-member audit and compensation committees

W. Thorpe McKenzie retired from the Board effective March 27, 2025.
April 1, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Director W. Thorpe McKenzie retires from XBiotech board effective March 27, 2025

McKenzie served since 2009; was on Audit, Compensation, and Nominating Committees.
December 31, 2024, 6:59 PM ET leadership materiality 0.30 positive item 5.02

XBiotech appoints renowned immunologist Dr. Tak W. Mak to its Board of Directors

Dr. Mak appointed December 24, 2024 to fill board vacancy; will serve until next annual meeting.
June 20, 2024, 7:59 PM ET other materiality 0.05 neutral item 5.07

XBiotech stockholders elect five directors and ratify auditor at annual meeting

Proposal 1: Five directors elected; John Simard received 9,032,922.58 votes for, Jan-Paul Waldin 7,407,212.58, W. Thorpe McKenzie 8,485,018.58, Donald MacAdam 8,817,755.58, Peter Libby 9,040,330.58.
January 4, 2024, 6:59 PM ET debt materiality 0.65 positive item 1.01 item 2.03 item 3.02 item 8.01 item 9.01 ◈ Debt Financings◈ Material Agreements

XBiotech enters $10M convertible loan from CEO to fund new R&D facility

$10M loan from CEO John Simard at 8% simple interest, secured by real estate and cash.

Executive changes

Departed

W. Thorpe McKenzie

Director

XBIT · XBiotech Inc.

Effective: 2025-03-27
Filed: April 1, 2025, 7:59 PM ET

On March 27, 2025, W. Thorpe McKenzie informed the Board of Directors (the “Board”) of XBiotech Inc. (the “Company”) via letter of his decision to retire from the Board, effective immediately.

Materiality & sentiment trend

Max materiality 0.70 · Median 0.30 · Most common event leadership

2 positive 0 negative 8 neutral

source · XBIT on sec.gov